Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-center, open-label, randomized and controlled phase III study of GFH925 treating refractory metastatic colorectal cancer (CRC) patients

Next Previous
Trial Profile

A multi-center, open-label, randomized and controlled phase III study of GFH925 treating refractory metastatic colorectal cancer (CRC) patients

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 29 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fulzerasib (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions

Most Recent Events

  • 29 Apr 2024 New trial record
  • 19 Apr 2024 According to a GenFleet Therapeutics media release, US Food and Drug Administration (FDA) has granted the clinical trial approval for GFH925 registrational monotherapy trial in treating refractory metastatic colorectal cancer (CRC) patients.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top